Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 7/20 | 0.39 |
| ▸ | SKP1 | P63208 | 7/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 7/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344553 | 0.84 | CHRM4 (0.47) | CKS1BSKP1SKP2DGAT1CHRM4 | |
| SCHEMBL345491 | 0.80 | ENPP2 (0.43) | CKS1BSKP1SKP2DGAT1CHRM4 | |
| SCHEMBL2334744 | 0.80 | CHRM4 (0.48) | CHRM4LMNA | |
| SCHEMBL1727978 | 0.74 | KDM1A (0.43) | DGAT1KDM4EABL1LMNA | |
| SCHEMBL9993136 | 0.73 | HSD17B10 (0.36) | DGAT1GPR119KDM4ELMNA | |
| SCHEMBL1730190 | 0.72 | CHRM4 (0.44) | DGAT1CHRM4KDM4EABL1LMNA | |
| SCHEMBL1730164 | 0.72 | DEGS1 (0.47) | DGAT1CHRM4GPR119KDM4EABL1 | |
| SCHEMBL3793052 | 0.70 | HSD17B10 (0.37) | DGAT1GPR119KDM4E | |
| SCHEMBL1729688 | 0.70 | LMNA (0.59) | CHRM4KDM4EABL1LMNA | |
| SCHEMBL1727916 | 0.70 | ENPP2 (0.45) | DGAT1CHRM4GPR119KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CKS1B 1161/4885SKP1 4281/4885SKP2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.